The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis

Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society
Jodie M Burton, M S Freedman

Abstract

Multiple sclerosis (MS) is the most common nontraumatic neurological disorder of young adults, and roughly 85% of patients present with the relapsing form of the disease. Over the past 2 decades, the treatment arsenal for relapsing MS has expanded and evolved from mildly effective and relatively benign injectable agents to potent cell-depleting monoclonal agents. The latter have the potential to achieve disease remission coupled with risk of moderate to severe adverse events with which all MS care providers will need to acquaint themselves. This review is based on a detailed assessment of MS pivotal trials, extension studies, and expert reviews of the agents discussed. The following review should aid those practitioners directly and indirectly involved in the care of MS patients in understanding the benefits and risks associated with the medications they prescribe.

References

Mar 3, 2006·The New England Journal of Medicine·Chris H PolmanUNKNOWN AFFIRM Investigators
Mar 3, 2006·The New England Journal of Medicine·Richard A RudickUNKNOWN SENTINEL Investigators
Jan 22, 2010·The New England Journal of Medicine·Ludwig KapposUNKNOWN FREEDOMS Study Group
Jan 22, 2010·The New England Journal of Medicine·Jeffrey A CohenUNKNOWN TRANSFORMS Study Group
Jan 22, 2010·The New England Journal of Medicine·Gavin GiovannoniUNKNOWN CLARITY Study Group
Apr 27, 2011·Annals of Neurology·Jeffrey A Cohen, Jerold Chun
Oct 14, 2011·The New England Journal of Medicine·Paul O'ConnorUNKNOWN TEMSO Trial Group
Jul 5, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Jack Simon
Sep 21, 2012·The New England Journal of Medicine·Robert J FoxUNKNOWN CONFIRM Study Investigators
Sep 21, 2012·The New England Journal of Medicine·Ralf GoldUNKNOWN DEFINE Study Investigators
Oct 31, 2012·The Journal of Cell Biology·Lawrence Steinman
Nov 30, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Harold L Atkins, Mark S Freedman
Apr 23, 2013·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Mark S FreedmanUNKNOWN Canadian Multiple Sclerosis Working Group
Oct 16, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Patrick VermerschUNKNOWN TENERE Trial Group
Oct 17, 2014·BMJ Case Reports·R AlroughaniA Thussu
Dec 22, 2016·The New England Journal of Medicine·Stephen L HauserUNKNOWN OPERA I and OPERA II Clinical Investigators
Aug 25, 2017·Neurology·Eva HavrdovaUNKNOWN CARE-MS I and CAMMS03409 Investigators
Aug 25, 2017·Neurology·Alasdair J ColesUNKNOWN CARE-MS II and CAMMS03409 Investigators
Sep 1, 2017·Expert Opinion on Pharmacotherapy·Trygve HolmøyKjell-Morten Myhr
Dec 17, 2017·Journal of the Neurological Sciences·Natalie E ParksDean M Wingerchuk

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.